去势抵抗性前列腺癌-话题@MedSci

#去势抵抗性前列腺癌#

112篇内容 | 2947人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1342110, encodeId=2c2413421105b, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Ann Oncol：非转移去势抵抗性前列腺癌中阿帕鲁他胺和总体存活率研究, objectType=article, longId=182477, objectId=9fb91824e7c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb91824e7c0, replyNumber=0, likeNumber=74, createdTime=2019-11-07, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb91824e7c0, moduleTitle=Ann Oncol：非转移去势抵抗性前列腺癌中阿帕鲁他胺和总体存活率研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb91824e7c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342109, encodeId=cac3134210926, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理, objectType=article, longId=181240, objectId=899218124028, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899218124028, replyNumber=0, likeNumber=27, createdTime=2019-10-16, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899218124028, moduleTitle=2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=899218124028)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342108, encodeId=12e81342108ec, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=64, createdTime=2019-10-06, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342107, encodeId=4160134210e46, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌, objectType=article, longId=180187, objectId=220318018e7e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=220318018e7e, replyNumber=0, likeNumber=69, createdTime=2019-09-28, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=220318018e7e, moduleTitle=Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=220318018e7e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342106, encodeId=eca713421066f, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer P D：膳食ω-3脂肪酸对去势抵抗性前列腺癌和肿瘤相关巨噬细胞的影响研究, objectType=article, longId=179236, objectId=887b1e92368d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=887b1e92368d, replyNumber=0, likeNumber=61, createdTime=2019-09-12, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=887b1e92368d, moduleTitle=Prostate Cancer P D：膳食ω-3脂肪酸对去势抵抗性前列腺癌和肿瘤相关巨噬细胞的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=887b1e92368d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342105, encodeId=6bbf13421057e, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, objectType=article, longId=178245, objectId=e1fa1e8245bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fa1e8245bc, replyNumber=0, likeNumber=59, createdTime=2019-08-29, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fa1e8245bc, moduleTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fa1e8245bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342104, encodeId=64a6134210410, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Oncogene：去势抵抗性前列腺癌中环状RNAs能够增加雄激素受体多样性, objectType=article, longId=178184, objectId=9dcd1e81844b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd1e81844b, replyNumber=0, likeNumber=102, createdTime=2019-08-27, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd1e81844b, moduleTitle=Oncogene：去势抵抗性前列腺癌中环状RNAs能够增加雄激素受体多样性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd1e81844b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342103, encodeId=59b113421034c, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理（草稿）, objectType=article, longId=176545, objectId=66fd1e6545d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66fd1e6545d6, replyNumber=0, likeNumber=39, createdTime=2019-08-01, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66fd1e6545d6, moduleTitle=2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理（草稿）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66fd1e6545d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342102, encodeId=fa2913421021d, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=AUA：恩杂鲁胺联合雄激素剥夺疗法可显着改善去势抵抗性前列腺癌, objectType=article, longId=165939, objectId=009f16593979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=009f16593979, replyNumber=0, likeNumber=89, createdTime=2019-05-14, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=009f16593979, moduleTitle=AUA：恩杂鲁胺联合雄激素剥夺疗法可显着改善去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=009f16593979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342101, encodeId=338e134210158, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Cancer：糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险, objectType=article, longId=165603, objectId=4efd165603a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4efd165603a7, replyNumber=0, likeNumber=80, createdTime=2019-05-09, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4efd165603a7, moduleTitle=Cancer：糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4efd165603a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342100, encodeId=4d00134210042, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Sci Rep：黑覆盆子及其鞣花酸和花青素成分对去势抵抗性前列腺癌细胞紫杉烷化疗的影响, objectType=article, longId=163080, objectId=593e16308060, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=593e16308060, replyNumber=0, likeNumber=84, createdTime=2019-03-29, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=593e16308060, moduleTitle=Sci Rep：黑覆盆子及其鞣花酸和花青素成分对去势抵抗性前列腺癌细胞紫杉烷化疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=593e16308060)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342099, encodeId=835b1342099d0, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Sci Rep：雄激素受体基因变异在循环无细胞DNA中作为生物标记在去势抵抗性前列腺癌中的应用研究, objectType=article, longId=162867, objectId=d16016286e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16016286e8c, replyNumber=0, likeNumber=58, createdTime=2019-03-26, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16016286e8c, moduleTitle=Sci Rep：雄激素受体基因变异在循环无细胞DNA中作为生物标记在去势抵抗性前列腺癌中的应用研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16016286e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342098, encodeId=bd6013420982b, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Nucleic Acids Res：揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制, objectType=article, longId=162510, objectId=b54a162510f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b54a162510f4, replyNumber=0, likeNumber=47, createdTime=2019-03-19, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b54a162510f4, moduleTitle=Nucleic Acids Res：揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b54a162510f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342097, encodeId=b86f134209e2a, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标, objectType=article, longId=162284, objectId=205b162284e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=205b162284e8, replyNumber=0, likeNumber=68, createdTime=2019-03-15, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=205b162284e8, moduleTitle=Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=205b162284e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342096, encodeId=194613420961e, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=162125, objectId=bf0c162125cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf0c162125cc, replyNumber=0, likeNumber=76, createdTime=2019-03-13, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf0c162125cc, moduleTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf0c162125cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342095, encodeId=11991342095f2, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, objectType=article, longId=161545, objectId=3b1a161545a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b1a161545a9, replyNumber=0, likeNumber=55, createdTime=2019-03-04, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b1a161545a9, moduleTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b1a161545a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342094, encodeId=48c213420942e, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, objectType=article, longId=161512, objectId=f0b416151215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b416151215, replyNumber=0, likeNumber=70, createdTime=2019-03-03, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b416151215, moduleTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b416151215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342093, encodeId=be911342093ef, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率, objectType=article, longId=160436, objectId=dab016043632, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dab016043632, replyNumber=0, likeNumber=78, createdTime=2019-02-20, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dab016043632, moduleTitle=Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dab016043632)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342092, encodeId=4a5a1342092e3, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, objectType=article, longId=160343, objectId=61541603433f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61541603433f, replyNumber=0, likeNumber=57, createdTime=2019-02-20, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61541603433f, moduleTitle=Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61541603433f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342091, encodeId=7ebd134209116, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, objectType=article, longId=160341, objectId=61af160341ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61af160341ee, replyNumber=0, likeNumber=72, createdTime=2019-02-19, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61af160341ee, moduleTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61af160341ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

去势抵抗性前列腺癌

2020-05-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Ann Oncol：非转移去势抵抗性前列腺癌中阿帕鲁他胺和总体存活率研究

2019-11-07

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理

2019-10-16

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌

2019-09-28

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer P D：膳食ω-3脂肪酸对去势抵抗性前列腺癌和肿瘤相关巨噬细胞的影响研究

2019-09-12

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功

2019-08-29

智慧医人 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Oncogene：去势抵抗性前列腺癌中环状RNAs能够增加雄激素受体多样性

2019-08-27

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

2019 CUA/CUOG指南：去势抵抗性前列腺癌的管理（草稿）

2019-08-01

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

AUA：恩杂鲁胺联合雄激素剥夺疗法可显着改善去势抵抗性前列腺癌

2019-05-14

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Cancer：糖尿病不良控制能够增加去势抵抗性前列腺癌和转移的风险

2019-05-09

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Sci Rep：黑覆盆子及其鞣花酸和花青素成分对去势抵抗性前列腺癌细胞紫杉烷化疗的影响

2019-03-29

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Sci Rep：雄激素受体基因变异在循环无细胞DNA中作为生物标记在去势抵抗性前列腺癌中的应用研究

2019-03-26

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Nucleic Acids Res：揭示长链非编码RNA PCAT1促进去势抵抗性前列腺癌进展的新机制

2019-03-19

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Prostate Cancer P D：MEK-ERK信号是转移去势抵抗性前列腺癌的治疗靶标

2019-03-15

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌

2019-03-13

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验

2019-03-04

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成

2019-03-03

hb2008ye (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Opdivo/Yervoy组合显著提高去势抵抗性前列腺癌患者响应率

2019-02-20

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Opdivo（nivolumab）联合Yervoy（ipilimumab）具有转移性去势抵抗性前列腺癌患者的治疗希望

2019-02-20

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS

2019-02-19

科室
- - 订阅+
  - 更多科室
工具
服务